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Gene Transfer into 
Cardiac Myocytes in vivo 
Leslie A. Leinwand and Jeffrey M. Leiden 
The ability to express recombinant genes in cardiac myocytes in vivo 
holds promise for the treatment of a number of inherited and acquired 
diseases of the cardiovascular system. Several groups have demon- 
strated recently that plasmid DNA is taken up and expressed in cardiac 
myocytes following injection into the left ventricular wall in vivo. 
Recombinant genes introduced into cardiac myocytes by this technique 
are expressed for at least 6 months after injection, and appear to be 
regulated normally by humoral signals. In addition to its potential for 
somatic gene therapy, this method should prove useful for studies of 
transcriptional regulation in the heart. (Trends Cardiovasc Med 1991; 
1:271-276) 
Somatic gene therapy can be defined as 
the ability to program the expression of 
recombinant genes in non-germ-line cells 
of a recipient host. Recent advances in 
molecular biologic techniques, includ- 
ing the cloning of a large number of 
eukaryotic and prokaryotic genes, and 
the development of viral and chemical 
gene delivery systems have brought us to 
the threshold of a new era of somatic 
gene therapy [reviewed by Friedmann 
(1989), Swain (1989)‘ and Nabel and 
Nabel (1991)]. A wide range of gene 
therapy experiments are being pursued 
in animal systems (Lemischka et al. 
1986; Hock and Miller 1986; Garver et al. 
1987; Palella et al. 1988; Dichek et al. 
1989; Nabel et al. 1990; Wilson et al. 
1989), and the first trials of human gene 
therapy have been initiated recently in 
patients with inherited enzyme deficien- 
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ties and malignancies (Rosenberg et al. 
1990). 
The ability to program recombinant 
gene expression in cardiac myocytes in 
vivo holds promise for the treatment of a 
number of disorders of the cardiovascu- 
lar system. Potential approaches to so- 
matic gene therapy in the heart can be 
divided into two groups. Indirect gene 
therapy methods involve the introduc- 
tion of recombinant genes into recipient 
cells in vitro, followed by the transplan- 
tation of these transduced cells back into 
an appropriate host organism. Such 
indirect approaches utilizing cardiac my- 
ocytes have been restricted severely by 
our inability to grow and manipulate 
these cells in vitro. Normal neonatal and 
adult cardiac myocytes display a very 
limited life span in tissue culture (Zak 
1974), and only one cardiac cell line has 
been described (Steinhelper et al. 1990). 
Because this cell line was derived from 
an SV40 T-antigen transgenic animal 
and causes tumors when injected into 
nude mice, it may not represent an ideal 
reagent for studies of cardiac somatic 
gene therapy. 
A second type of approach to somatic 
gene therapy in the heart, direct gene 
transfer, involves the introduction of 
BRIEF REVIEWS 
recombinant genes into recipient cells of 
the intact heart in vivo, without the need 
to remove the cardiac myocytes from the 
host organism. Any such method of 
direct gene therapy must fulfill a number 
of requirements, including an efficient 
technique for delivering DNA into the 
target tissue, the ability to program 
stable expression in the correct cell type, 
and a minimal risk of harmful side 
effects to the recipient organism. Thus 
far, three types of approaches have been 
used to deliver DNA into an intact organ. 
The first involves the use of biochemical 
delivery systems in which the DNA is 
complexed with a variety of materials, 
including liposomes (Wang and Huang 
1987; Felgner et al. 1987; Nicolau et al. 
1983; Nabel et al. 1990), polylysine- 
glycoprotein (Wu et al. 1989), and a 
calcium-phosphate precipitate. The sec- 
ond approach involves the use of viral 
transduction systems in which the ex- 
ogenous gene is incorporated into a 
recombinant viral genome that is then 
used to infect cells within the organ [for 
the cardiovascular system, see Nabel et 
al. (1990)]. The third method, which is 
rather remarkable for its simplicity, in- 
volves the direct injection of purified 
DNA into adult tissues. This approach 
was first demonstrated in mouse skeletal 
muscle (Wolff et al. 1990). Recently, 
several groups have demonstrated that 
this type of direct injection approach can 
be used to program recombinant gene 
expression in adult rodent cardiac my- 
ocytes in vivo (Lin et al. 1990; Acsadi et 
al. 1991; Kitsis et al. 1991). This review 
describes the results of these initial 
experiments, with particular emphasis 
on the efficiency, stability, and safety of 
recombinant gene expression in the heart. 
In addition, we address the question of 
whether such recombinant genes are 
regulated normally in response to physi- 
ologic stimuli following their introduc- 
tion into cardiac myocytes in vivo. 
l Efficiency and Stability of Gene 
Transduction into Cardiac 
Myocytes in vivo 
Wolff et al. (1990) were the first to 
demonstrate that recombinant genes 
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Figure 1. Reporter plasmids used for cardiac injections. Schematic representations of the 
reporter plasmids used in studies of recombinant gene expression in cardiac myocytes in vivo. 
The Rous sarcoma virus long-terminal repeat (RSV LTR) containing the viral promoter and 
enhancer sequences and the 6 13 bp CL myosin heavy-chain promoter (a-cardiac MHC promoter) 
are shown as open boxes. The chloramphenicol acetyltransferase (CAT), luciferase, and 
8-galactosidase reporter genes are shown as hatched boxes. The SV40 sequences containing the 
polyadenylation site and small t intron are shown as the solid at-row. 
could be taken up and expressed in a 
small percentage of murine skeletal myo- 
fibers following direct intramuscular in- 
jection of purified DNA or RNA. The 
mechanisms underlying nucleic acid up- 
take by skeletal muscle remain unclear, 
but expression of the recombinant genes 
was shown to be stable for at least 2 
months following injection. Three labo- 
ratories have now used similar direct 
DNA injection methods to express re- 
combinant genes in the heart (Lin et al. 
1990; Acsadi et al. 1991; Kitsis et al. 
1991). As shown in Figure 1, these 
experiments have involved the use of 
three different reporter genes: chloram- 
phenicol acetyltransferase (CAT), lucif- 
erase (Luc), and P-galactosidase @gal>. 
These reporter genes were chosen be- 
cause none of them are normally ex- 
pressed in cardiac myocytes, and be- 
cause each can be easily assayed in vitro. 
CAT is a bacterial enzyme that is easily 
quantified by thin-layer chromatogra- 
phy. Luciferase is a firefly enzyme that 
generates light in the presence of ade- 
nosine triphosphate and a specific sub- 
strate. It has the advantage of being 
more sensitive than CAT so that lower 
levels of expression can be detected. 
P-Galactosidase is a bacterial enzyme 
that has the advantage of being assaya- 
ble both histochemically (in the presence 
of an appropriate substrate, it catalyzes a 
reaction that stains cells blue) and bio- 
chemically. Thus, it can be used to 
identify cells expressing recombinant 
gene products in vivo. The ability to 
identify P-galactosidase expression histo- 
chemically is particularly important in 
the heart, in which <50% of the cells are 
cardiac myocytes. 
Both viral and cellular transcriptional 
regulatory sequences have been used in 
the initial studies of recombinant gene 
expression in cardiac muscle. The Rous 
sarcoma virus long-terminal repeat (RSV 
LTR), which contains both promoter 
and enhancer sequences, has proven to 
be a useful transcriptional regulatory 
element, because previous work has 
shown that it programs high-level tran- 
scription in cardiac myocytes both in 
vitro (Gustafson et al. 1987) and in vivo 
(Overbeek et al. 1986). Similarly, the a 
cardiac myosin heavy-chain (aMHC) gene 
is expressed in a cardiac-specific manner 
and is positively regulated by thyroid 
hormone (Izumo et al. 1986; Lompre et 
al. 1984). The promoter and flanking 
sequence have been shown to be active in 
transfected myocytes and to be respon- 
sive in vitro to thyroid hormone (Gus- 
tafson et al. 1987; Tsika et al. 1990). 
Thus, this promoter is useful for studies 
of the humoral regulation of recombi- 
nant genes in cardiac myocytes in vivo. 
The direct DNA injection methods 
used in the three studies were similar. 
Each of the groups utilized a narrow 
(27-30 gauge) needle to inject solutions 
of purified supercoiled plasmid DNA. 
The vehicle used for DNA injection ap- 
pears to be relatively unimportant, with 
successful gene transfer resulting from 
the use of Opti-MEM, normal saline, and 
5%-20% sucrose in either phosphate- 
buffered saline or water. In general, 
large quantities of DNA have been used 
for injection, with a linear dose respon- 
siveness seen, at least in skeletal muscle, 
between 10 and 100 pg of DNA (Wolff et 
al. 1990). Similarly, it appears that the 
success of the injection technique is 
independent of the type of anesthesia 
used and the method of ventilation. 
Taken together, these studies have 
provided us with complementary quanti- 
tative and qualitative data concerning 
recombinant gene expression in the heart. 
Specifically, they have addressed the 
following important questions: (a) What 
cells can be induced to express recombi- 
nant genes following injection of DNA? 
(b) How efficient is recombinant gene 
expression? (c) How stable is recombi- 
nant gene expression? (d) Can recombi- 
nant genes introduced into cardiac my- 
ocytes be regulated in response to hu- 
moral signals? In an initial set of studies, 
Leiden and coworkers (Lin et al. 1990) 
injected the pRSV-pgal plasmid (see 
Figure 1) directly into the apical portion 
of the beating left ventricular wall of 6- to 
1 l-week-old rat hearts. Rats were killed 
either 3-5 days or 3-4 weeks following 
injection, and sections of the injected 
hearts were stained for P-galactosidase 
activity. These studies demonstrated re- 
combinant 8-galactosidase activity in 
>75% of injected hearts at both 3-5 days 
and 3-4 weeks following injection (Fig- 
ure 2). P-Galactosidase was detected 
histochemically only in cardiac myocytes 
(and not in fibroblasts or vascular cells) 
and only in the area of DNA injection. 
Recombinant gene expression was a 
relatively low-frequency event, occur- 
ring in cl/100 myocytes in the area of 
injection. However, the absolute levels of 
P_galactosidase expression were not quan- 
tified in these studies. In control experi- 
ments, no P-galactosidase activity was 
detected in rat hearts injected with either 
vehicle alone or an irrelevant control 
plasmid. Recent follow-up studies have 
shown that 8-galactosidase can still be 
detected 5-6 months following injection 
of pRSV+gal into 6-week-old rat hearts 
(E. Barr and J. Leiden, unpublished 
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observations, 1991). Finally, histologic 
examination of the injected hearts demon- 
strated an acute inflammatory response 
in the area of injection at 34 days that 
often evolved into a fibrous scar by 4 
weeks following injection. This inflam- 
matory reaction, which was composed of 
both mononuclear and polymorphonu- 
clear leukocytes, did not appear to repre- 
sent a response to the injected DNA, as it 
was also observed following injection of 
vehicle (5% sucrose in PBS). 
In a second set of studies, Leinwand 
and coworkers (Kitsis et al. 1991) in- 
jected the pRSV-CAT and paMHC-Luc 
(Figure 1) plasmids into the left ventricu- 
lar wall of Sprague-Dawley rats and 
assayed homogenates of the injected 
hearts for CAT and luciferase activity 5 
days following injection. In addition, 
they injected the same plasmids into rat 
skeletal muscle (adductor magnus) to 
compare the efficiency of recombinant 
gene expression in cardiac and skeletal 
myocytes. These experiments demon- 
strated recombinant gene expression in 
100% of the hearts and 78% of the 
skeletal muscles of injected animals. 
Interestingly, rat hearts expressed 10- 
100 times more CAT activity per micro- 
gram of protein lysate than skeletal 
muscle injected with the same amount of 
pRSV-CAT DNA (Figure 3). The reason 
for this difference remains obscure, but 
could be due to differences in the effi- 
ciency of DNA uptake or expression. CAT 
and luciferase activities were detected in 
100% of the hearts at 14 days and 40% of 
the hearts at 60 days (P. Buttrick, M. 
Kaplan, and L. Leinwand, unpublished 
observations, 199 1). In contemplating 
this approach to gene therapy, one 
consideration is the quantity of gene 
product produced by the injected gene. 
Use of the sensitive luciferase reporter 
gene enabled quantification of the amount 
of recombinant gene product being pro- 
duced in the heart. The RSV promoter 
led to the production of 400-600 pg of 
luciferase activity per heart 5-14 days 
after injection. 
In a third study, Wolff and coworkers 
(Acsadi et al. 1991) extended their origi- 
nal observations concerning recombi- 
nant gene expression in skeletal muscle 
fibers to cardiac muscle. Specifically, 
they showed that g-galactosidase, lucif- 
erase, and CAT genes under the control 
of the RSV LTR were expressed in 
cardiac myocytes following injection into 
Figure 2. Expression of the recombinant P-galactosidase @gal) gene in cardiac myocytes in 
vivo following direct injection of pRSV (Row sarcoma virus)-8gal DNA into the left ventricular 
wall; 100 pg of pRSV-8gal DNA was injected into the beating apical wall of the left ventricle of 
Sprague-Dawley rats with use of a 30-gauge needle. Hearts were harvested 3-5 days or 3-4 
weeks after injection and stained for 8-galactosidase activity. (A) 10x view of a 3-mm section of 
a heart 3 days after pRSV-pgal injection. (B) 18x view of a 3-mm section from a heart 27 days 
after pRSV+gal injection. (C and D) 125x and 250x views, respectively, of 4-pm sections from 
a heart 3 days after pRSV-8gal injection. P-Galactosidase activity (dark blue staining) is seen 
only within cardiac myocytes, which can be identified by their myofibrillar architecture. From 
Lin et al. (1990). 
Figure 3. Heart and skeletal muscles express injected genes. Chloramphenicol acetyltrans- 
ferase (CAT) activities in rat skeletal muscles (S) and hearts (H) coinjected with 100 ug each of 
pRSV-CAT and pa cardiac myosin heavy-chain (MHC)-luciferase (Luc) are shown; 20% of each 
organ homogenate was assayed 5 days after DNA injection. The above autoradiogram resulted 
from a 12-h exposure. Percent chloramphenicol conversion is indicated below each lane. Plus 
and minus correspond to positive and negative controls consisting of homogenization buffer 
with or without partially purified Escherichia coli CAT From Kitsis et al. (1991). 
SSSSSHHHH+- 
Percent 
Conversion: 2.2 0.4 0.1 1.9 0.5 30.4 20.1 47.0 68.8 
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the beating left ventricular wall of adult 
Sprague-Dawley rats. In contrast to the 
results reported by Leiden and Lein- 
wand, Wolffs group found that CAT and 
luciferase expression was detectable for 
c25 days after injection. Because recom- 
binant gene expression could be stabi- 
lized for at least 60 days by immunosup- 
pression of the injected rats with cy- 
closporin A, they attributed the observed 
instability of expression to an immune 
response against the recombinant gene 
products. This hypothesis was further 
supported by the finding that luciferase 
expression also appeared to be stable for 
at least 60 days in nude rat hearts 
injected with the pRSV-Luc plasmid. 
The reason for the differences in the 
stability of recombinant gene expression 
observed by Wolffs group as compared 
with the results of Leinwand and Leiden 
remains unclear. However, Wolff and 
coworkers injected plasmid DNA in nor- 
mal saline while both Leinwand and 
Leiden injected DNA in PBS-sucrose. 
An important concern with all models 
of gene therapy is the potential for 
damage to host cells by integration of 
recombinant genes into the host 
genome. To address this issue directly, 
Acsadi et al. (1991) used Southern-blot 
analyses to demonstrate that the bulk of 
the recombinant DNA in cardiac my- 
ocytes from the injected hearts is retained 
in closed circular and linear forms and 
has not been integrated into the host 
genome. Although small amounts of inte- 
grated DNA probably would not be de- 
tected by use of these approaches, this 
finding is important because it suggests 
that this method of introducing recombi- 
nant genes into cardiac myocytes may 
not pose a significant risk of mutagene- 
sis of the recipient cells. 
l Regulation of Recombinant Genes 
in Cardiac Myocytes 
The ability to achieve gene transfer 
through direct DNA injection offers a 
straightforward means of studying gene 
regulation in vivo. This approach is 
clearly simpler and less costly than the 
generation of transgenic animals, which 
has traditionally been the only means of 
studying the response of gene sequences 
to complex physiologic stimuli. The study 
of cardiac gene regulation has been 
largely restricted to the transfection of 
cultured fetal or neonatal cardiomy- 
ocytes. While useful, these studies have 
been limited by two factors. First, car- 
diac myocytes do not divide in culture. 
Second, it is not possible to study the 
effects of complex physiologic phenom- 
ena such as hypertension in a cell culture 
environment. 
To apply direct gene transfer to the 
study of cardiac gene regulation, it was 
necessary to demonstrate that an in- 
jected gene would be regulated ap- 
propriately. Experiments were designed 
to ask whether a cardiac-specific pro- 
moter would direct expression of a re- 
porter gene in a tissue-restricted and 
hormonally responsive manner (Kitsis et 
al. 1991). The rat aMHC promoter was 
chosen for these studies because the 
expression of this gene in vivo is re- 
stricted to the heart and is positively 
regulated by thyroid hormone. Upstream 
of the aMHC gene, 613 base pairs of 
DNA were linked to the luciferase re- 
porter gene to produce the paMHC-Luc 
plasmid (Figure l), which was injected 
into both cardiac and skeletal muscle. In 
these experiments, organs were always 
coinjected with the pRSV-CAT reference 
plasmid as an internal control. Lucif- 
erase activity was then normalized to 
CAT activity to control for animal-to- 
animal variability as well as for known 
differences in transfection efficiencies 
between cardiac and skeletal muscle (see 
Figure 3). Luciferase activity was de- 
tected at high levels in heart, but not in 
skeletal muscle. Therefore, expression of 
an injected gene driven by a cellular 
promoter was regulated in the manner of 
the endogenous myosin heavy-chain gene. 
To address the ability to modulate the 
expression of an injected gene, the influ- 
ence of thyroid hormone on the expres- 
sion of injected paMHC-Luc was stud- 
ied. aMHC mRNA and protein are posi- 
tively regulated by thyroid hormone in 
vivo, and a construct bearing the same 5’ 
flanking region used in the injections has 
been shown to confer thyroid hormone 
responsiveness to a reporter gene trans- 
fected into fetal cardiac myocytes (Tsika 
et al. 1990). However, the regulatory 
elements of this gene have not been 
mapped in vivo, nor has it been possible 
to assess the thyroid responsiveness of 
DNA constructs in the adult heart. To 
assess the ability of paMHC-Luc to 
respond to thyroid hormone, animals 
were made hypothyroid and then hyper- 
thyroid, and their hearts were coinjected 
with paMHGLuc and pRSV-CAT. Of 
note, CAT activity from the injected 
RSV-CAT plasmid was significantly de- 
pressed in hyperthyroid relative to euthy- 
roid and hypothyroid animals. Since the 
RSV promoter is not known to be re- 
sponsive to thyroid hormone, this obser- 
vation points to the need to include 
reference plasmids to control for varia- 
tions in the transfection efficiency of 
organs in different physiologic states. 
The mean LucKAT ratio of hyperthyroid 
animals was 2-3 times greater than that 
of euthyroid or hypothyroid animals 
(Figure 4). These results, coupled with 
the tissue-restricted expression of the 
injected paMHC-Luc plasmid, strongly 
suggested that expression of injected 
genes can be targeted to cardiac my- 
ocytes by use of a cardiac-specific pro- 
moter, and that their expression can be 
modulated by the hormonal status of the 
animal. 
l Summary and Future Directions 
It is clear from the studies summarized 
above that recombinant genes can be 
introduced into and expressed in cardiac 
myocytes following direct injection of 
plasmid DNA into the left ventricular 
wall of rodents. Although the methods 
employed and conclusions reached by 
the three laboratories involved in this 
work vary slightly, the results are most 
remarkable for their consistency and 
reproducibility. Taken together, these 
studies have demonstrated (a) that di- 
rectly injected recombinant DNA is taken 
up and expressed by a small percentage 
of cardiac myocytes in the area of injec- 
tion, (b) that the level of recombinant 
gene expression in heart appears to be 
higher than that observed in skeletal 
muscle following similar DNA injec- 
tions, and (c) that the injected genes 
appear to be regulated normally by 
humoral signals. The stability of re- 
combinant gene expression following 
direct DNA injections remains contro- 
versial and may be effected by an im- 
mune response directed against the re- 
combinant gene products. Finally, the 
ability to introduce recombinant genes 
into eukaryotic tissues in vivo by direct 
injection appears to be limited to skeletal 
and cardiac muscle (Acsadi et al. 1991). 
The molecular mechanisms that facili- 
tate DNA uptake in striated muscle 
remain unclear, but the possibilities 
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Figure 4. Thyroid hormone modulation of the expression of a gene injected into heart muscle. 
Activities of CAT and luciferase in hearts coinjected with paMHC-Luc and pRSV-CAT from 
thyroid-hormone-manipulated animals. (A and B) CAT activities (% conversion; 15% 
homogenate) and LucKAT ratios [raw luminometer units; 5% homogenate]/[% conversion; 
15% homogenate] in hearts from hypothyroid animals (-T3) (n=6), hypothyroid animals treated 
with T3 (+T3) (n=6), and euthyroid controls (CON) (n=.5). An asterisk indicates a significance 
value: *p-co.05 and **pp<O.O05. Data are expressed as mean f SEM. From Kitsis et al. (1991). 
include specialized striated muscle trans- 
port systems such as the T tubules or the 
unique ability to disrupt the sarcolemma 
transiently during recombinant DNA in- 
jections. 
Regardless of the underlying mech- 
anism, direct injection of plasmid DNA 
has several unique advantages as com- 
pared with other previously described 
methods of somatic gene therapy. First, 
the direct-injection method obviates the 
need for viral vectors with their concom- 
itant risk of persistent infection of the 
recipient host. Secondly, it appears that 
the injected DNA is taken up and re- 
tained by myocytes in an episomal (that 
is, nonintegrated) form. Thus, the risk of 
mutagenesis of the recipient cells may be 
minimized, particularly as compared 
with retroviral vectors that usually inte- 
grate into the host genome. Finally, this 
method allows for the introduction of 
recombinant genes directly into cardiac 
myocytes in vivo, without the need for 
prior isolation and manipulation in tis- 
sue culture, a requirement that would 
render transfection of cardiac myocytes 
particularly difficult. 
Direct injection of recombinant DNA 
into the myocardium holds promise for 
the treatment of a number of inherited 
and acquired diseases of the cardiovas- 
cular system. At least three types of 
applications are currently being explored. 
. 
-T3 CON .T3 
First, experiments are under way to 
express recombinant angiogenesis fac- 
tors in cardiac myocytes in an attempt to 
stimulate collateral circulation in areas 
of ischemic myocardium (E. Barr, G. 
Englemann, and J. Leiden, unpublished 
results, 1991). This type of application 
has the advantage of not necessarily 
requiring recombinant gene expression 
by large numbers of cardiac myocytes. 
The technique is also being explored as a 
method of treating inherited defects of 
cardiac muscle proteins such as Duch- 
enne’s muscular dystrophy (abnormal 
dystrophin expression) and familial 
hypertrophic cardiomyopathy (abnormal 
PMHC expression). Finally, this method 
might be employed to replace circulating 
proteins in patients with inherited serum 
protein deficiencies. Recent preliminary 
studies have demonstrated that low lev- 
els of circulating human growth 
hormone (0.15 ngiml) can be produced 
in rats following direct injection of 100 
pg of a plasmid containing the human 
growth hormone gene under the control 
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of the RSV LTR (E. Barr and J. Leiden, 
unpublished results, 1991). 
Apart from its potential therapeutic 
applications, the DNA injection tech- 
nique represents a powerful tool for 
basic studies of cardiac transcription. 
Such studies have been limited in the 
past by the lack of a stable and trans- 
fectable cardiac cell line, and the sub- 
stantial expense and time involved in 
using transgenic systems to study tran- 
scriptional regulation in the heart. These 
studies can now be carried out in 3-5 
days after injection of appropriate re- 
porter constructs into rodent myo- 
cardium. Moreover, the method rep- 
resents a simple and economical way to 
test the promoter and enhancer elements 
of transgenic constructs prior to embryo 
injections. 
Although the direct-injection method 
described in this review represents the 
first step toward somatic gene therapy 
in the heart, a number of questions and 
problems must be addressed before it 
becomes a viable therapeutic modality. 
First, it must be determined that human 
myocytes, like their rodent counter- 
parts, can take up and express injected 
DNA. In addition, the stability of recom- 
binant gene expression must be investi- 
gated more fully, with particular empha- 
sis on the relationships between injec- 
tion technique, recipient species, and 
different recombinant proteins, and the 
potential immune and inflammatory re- 
sponses evoked by DNA injection. Fi- 
nally, the current injection methods 
must be modified in an attempt to 
increase the efficiency of recombinant 
gene transduction and to decrease the 
inflammatory response following DNA 
injection. Potentially useful changes in- 
clude alterations in the injection solu- 
tion, the use of DC shock prior to or 
following DNA injection, the induction 
of transient ischemia at the time of 
injection, the use of cardiac perfusion 
with DNA-containing solutions as an 
alternative to direct injection, and the 
use of local and/or systemic antiinflamma- 
tory agents. Although each of these 
problems represents a substantial tech- 
nical and experimental challenge, the 
initial success with direct injection of 
DNA into myocardium suggests that this 
technique may eventually lead to novel 
approaches for the therapy of cardio- 
vascular disease. 
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